Insulin Discontinuation Tension; FDA OKs Osteopenia Belt; Limited Mounjaro Supply

Type 1 diabetes patients are upset over the looming discontinuation of Novo Nordisk’s long-acting insulin detemir (Levemir). (USA Today)

Mid-life women with greater exposure to toxic metals like arsenic, cadmium, and mercury may produce fewer eggs. (Journal of Clinical Endocrinology & Metabolism)

The FDA cleared Bone Health Technologies’ Osteoboost as the first non-pharmacological device-based prescription treatment for postmenopausal women with osteopenia, the company announced.

While more weight loss within the first year of a diabetes diagnosis was linked with remission, people seldom kept the weight off long-term. (PLOS Medicine)

The 12.5-mg dose of the type 2 diabetes drug tirzepatide (Mounjaro) will have limited availability throughout February due to increased demand. Other doses will still be available. (Reuters)

Shortages affecting access to GLP-1 receptor agonists like tirzepatide and semaglutide (Ozempic, Wegovy) have increased the potential for fakes, the WHO warned.

Under a new policy, the Defense Department will extend coverage of in-vitro fertilization to service members in any relationship status. (Military Times)

Meanwhile in New Jersey, health insurance coverage for infertility services will be expanded to now include LGBTQ+ individuals. (CBS News)

More recent drug developments and approvals are finally pushing menopause mainstream. (Time)

Beginning in April, North Carolina’s state health plan will end state employees’ coverage of semaglutide and other pricey drugs for weight loss. (New York Times)

Please enable JavaScript to view the

comments powered by Disqus.